ONCGNOSTICS GMBH

oncgnostics develops - based on proprietary epigenetic biomarkers - highly reliable in vitro diagnostic (=IVD) tests for screening, therapeutic decisions and follow-up care in cancer diagnostics. The diagnostic tests developed by oncgnostics are based on DNA regions specifically methylated in precancerous and carcinoma cells. These marker regions are detected using well-established PCR-based technologies, which can be performed in routine molecular diagnostics laboratories with standard equipment. oncgnostics has identified novel markers for detecting cervical precancerous lesions and carcinomas.